glp-1 weight loss clinic wichita Home Medical Weight Loss Kansas City

If GLP-1 is right for you, your treatment ships directly to your home in Arizona

Now, two new late-phase clinical trials, sponsored by Eli Lilly and Company, suggest that transitioning from high dose injectable weight loss medications to either a daily pill or a lower maintenance dose can help people living with obesity to keep off most of the weight they have already lost The results of the ATTAIN-MAINTAIN and SURMOUNT-MAINTAIN trials were presented at the European Congress on Obesity and published in Previous research suggests that 1 year after stopping weight loss medication, people may regain, on average, 60% of their lost weight

In August 2025, Hengrui Medicine advanced its oral small-molecule GLP-1 candidate HRS-7535 into late-stage development, emphasizing local capability in producing affordable oral treatments that improve patient compliance

Patients are encouraged to report suspected side effects via the MHRA Yellow Card scheme (yellowcard.mhra.gov.uk)

Common adverse effects include gastrointestinal symptoms such as nausea, vomiting, diarrhea, and constipation, which typically diminish over time with continued use and gradual dose escalation